Begin typing your search...

Dr Reddy's Srikakulam plant gets VAI status from USFDA

image for illustrative purpose

Dr Reddys posts 1 pc drop in net profit at Rs 1,392 crore in Q1, revenue up 14 pc
X

22 Oct 2025 10:54 AM IST

Hyderabad: Hyderabad-based pharmaceutical company Dr. Reddy’s Laboratories on Tuesday announced that its manufacturing facility in Srikakulam, Andhra Pradesh, has received a "Voluntary Action Indicated" (VAI) status from the US Food and Drug Administration (USFDA).

The company shared this information with the stock exchanges and said it received the Establishment Inspection Report (EIR) on October 20.

According to the company, the inspection by the USFDA is now officially closed. The VAI classification means that the US health regulator found some issues at the facility, but it does not plan to take any regulatory or administrative action at this time.

"We wish to inform you that the company has received the Establishment Inspection Report (EIR) on October 20, 2025. The USFDA has classified the inspection outcome as 'Voluntary Action Indicated (VAI)'," it said, adding the inspection is officially closed.

Dr. Reddy’s Laboratories USFDA inspection Srikakulam manufacturing facility Voluntary Action Indicated (VAI) Establishment Inspection Report (EIR) pharmaceutical manufacturing regulatory compliance Andhra Pradesh pharma sector US health regulator FDA classification inspection closure company announcement drug manufacturing standards global pharmaceutical exports India pharma industry regulatory update 2025 Dr Reddy 
Next Story
Share it